Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function...

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Clear cell renal cell carcinoma (ccRCC) is often linked to Von Hippel-Lindau (VHL) gene mutations.
• Belzutifan targets hypoxia-induced factor-2α, showing efficacy in VHL-associated tumors.

Observation:

• This study examined belzutifan monotherapy in two advanced ccRCC patients with somatic VHL mutations.
• Both patients experienced rapid and sustained responses to the treatment.

Findings:

• Belzutifan demonstrated effectiveness in ccRCC patients with somatic VHL loss-of-function mutations.
• The drug showed potential even in patients experiencing pulmonary crises.

Implications:

• Belzutifan may be a valuable second or subsequent line of therapy for ccRCC with somatic VHL mutations.
• These findings highlight belzutifan's utility in managing advanced ccRCC, including critical presentations.